An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
Lynda Vuong(King's College Hospital), Alison C. MacKinnon(Centre for Inflammation Research)
Cited by 140
Related Papers
Regulation of Alternative Macrophage Activation by Galectin-3
|The Journal of Immunology|2008|29